[
  {
    "sentence": "Update searches run in April 2017 yielded a further 1166 records (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The authors reported no difference regarding CRT and a smaller but statistically significant number of injections with aflibercept versus ranibizumab.Excluded studies\nSee 'Characteristics of excluded studies' table for the list of exclusions with reasons.Risk of bias in included studies\nSee 'Risk of bias in included studies'; Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 presents the corresponding networks' structure.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4, Figure 5 and Figure 6 present forest plots with effects for each study, estimates from direct pairwise meta‐analysis and mixed estimate from the network meta‐analysis.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Mean risk of bias was low for mixed and direct comparisons among aflibercept, bevacizumab and ranibizumab for all efficacy outcomes, except for the comparison between bevacizumab and ranibizumab regarding mean BCVA change and mean CRT change, which were judged at unclear risk of bias (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "DRCRnet 2015 found that such subgroup differences were attenuated at two years.Safety at the longest available follow‐up\nTable 9 presents the number of studies (participants/eyes) in the network for safety outcomes at the longest available follow‐up, and Figure 8 presents the corresponding network structure.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Figure 9, Figure 10 and Figure 11 present forest plots for each study as well as their direct meta‐analysis and mixed estimates from the network meta‐analysis.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Regarding ATC arterial thromboembolic events and all‐cause death, risk of bias was low for aflibercept versus ranibizumab but it was unclear or high for bevacizumab versus ranibizumab (Figure 7).Quality of the evidence\nSee above for the discussion of risk of bias of mixed evidence in pairwise comparisons of interest.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Study\nParticipants\nInterventions\n\nMean n.injections\n\n\nVisualacuity (logMAR)\n\n\nRetinalthickness (µm)\n\n\nStudysponsor\n\n\n\nAhmadieh 2008\n78\nBevacizumabSham\n \n \n \nNone reported\n\n\nBOLT 2010\n80\nBevacizumabLaser\n9*3*\n0.590.61\n507482\nPublic\n\n\nDA VINCI 2011\n89\nAfliberceptLaser\n3.6 to 5.51.7\n0.55\n441\nIndustry\n\n\nDRCRnet 2010\n668\nLaserRanibizumab‐DLRanibizumab‐PL\n3*9*8*\n0.380.390.38\n \nPublic\n\n\nDRCRnet 2015\n620\nAfliberceptBevacizumabRanibizumab\n9.29.49.7\n0.40\n412414407\nPublic\n\n\nEkinci 2014\n100\nBevacizumabRanibizumab\n5.16.5\n0.220.24\n484490\nPublic\n\n\nIshibashi 2014\n233\nPegaptanibSham\n4\n0.56\n \nIndustry\n\n\nKorobelnik 2014\n268\nAfliberceptLaser\n8.52.4\n0.50\n \nIndustry\n\n\nLopez‐Galvez 2014\n83\nRanibizumabLaser\n5.32.1\n \n \nIndustry\n\n\nLUCIDATE 2014\n33\nLaserRanibizumab\n2.69\n0.420.30\n489455\nNo details\n\n\nMacugen 2005\n86\nPegaptanibSham\n54.5\n0.560.58\n476423\nIndustry\n\n\nMacugen 2011\n260\nPegaptanibSham\n8.38.4\n0.560.58\n442465\nIndustry\n\n\nRELATION 2012\n128\nLaserRanibizumab‐PL\n \n \n \nIndustry\n\n\nNepomuceno 2013\n60\nBevacizumabRanibizumab\n9.87.7\n0.600.63\n451421\nPublic\n\n\nREAD2 2009\n115\nLaserRanibizumabRanibizumab‐PL\n4.45.32.9\n0.600.540.60\n228190263\nIndustry\n\n\nRESOLVE 2010\n151\nRanibizumabSham\n10.28.9\n0.500.48\n455449\nIndustry\n\n\nRESPOND 2013\n203\nLaserRanibizumabRanibizumab‐PL\n9.28.8\n0.460.440.40\n458448422\nIndustry\n\n\nRESTORE 2011\n343\nLaserRanibizumabRanibizumab‐PL\n7.376.8\n0.460.400.42\n412427416\nIndustry\n\n\nREVEAL 2015\n390\nLaserRanibizumabRanibizumab‐PL\n1.97.87\n0.540.520.52\n395419430\nIndustry\n\n\nSoheilian 2007\n85\nBevacizumabLaser\n \n0.710.55\n352319\nPublic\n\n\nTurkoglu 2015\n70\nLaserRanibizumab\n \n0.840.80\n460488\nNone reported\n\n\nWiley 2016\n124\nBevacizumabRanibizumab\n33\n0.42\n477\nPublic\n\n\n\nOpen in a new tab\n\nDL: plus deferred laser \nPL: plus prompt laser\n(*): median, not mean, available and reported\nSelective reporting\nComparison adjusted funnel plots showed some asymmetry for the outcome 'gain of 3 or more VA lines', but no specific direct comparison seemed to be affected (Figure 12).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Update searches run in April 2017 yielded a further 1166 records (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Update searches run in April 2017 yielded a further 1166 records (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Risk of bias in included studies\nSee 'Risk of bias in included studies'; Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "See 'Risk of bias in included studies'; Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 3 presents the corresponding networks' structure.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4, Figure 5 and Figure 6 present forest plots with effects for each study, estimates from direct pairwise meta‐analysis and mixed estimate from the network meta‐analysis.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Mean risk of bias was low for mixed and direct comparisons among aflibercept, bevacizumab and ranibizumab for all efficacy outcomes, except for the comparison between bevacizumab and ranibizumab regarding mean BCVA change and mean CRT change, which were judged at unclear risk of bias (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "DRCRnet 2015 found that such subgroup differences were attenuated at two years.Safety at the longest available follow‐up\nTable 9 presents the number of studies (participants/eyes) in the network for safety outcomes at the longest available follow‐up, and Figure 8 presents the corresponding network structure.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Figure 9, Figure 10 and Figure 11 present forest plots for each study as well as their direct meta‐analysis and mixed estimates from the network meta‐analysis.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Regarding ATC arterial thromboembolic events and all‐cause death, risk of bias was low for aflibercept versus ranibizumab but it was unclear or high for bevacizumab versus ranibizumab (Figure 7).Quality of the evidence\nSee above for the discussion of risk of bias of mixed evidence in pairwise comparisons of interest.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Study\nParticipants\nInterventions\n\nMean n.injections\n\n\nVisualacuity (logMAR)\n\n\nRetinalthickness (µm)\n\n\nStudysponsor\n\n\n\nAhmadieh 2008\n78\nBevacizumabSham\n \n \n \nNone reported\n\n\nBOLT 2010\n80\nBevacizumabLaser\n9*3*\n0.590.61\n507482\nPublic\n\n\nDA VINCI 2011\n89\nAfliberceptLaser\n3.6 to 5.51.7\n0.55\n441\nIndustry\n\n\nDRCRnet 2010\n668\nLaserRanibizumab‐DLRanibizumab‐PL\n3*9*8*\n0.380.390.38\n \nPublic\n\n\nDRCRnet 2015\n620\nAfliberceptBevacizumabRanibizumab\n9.29.49.7\n0.40\n412414407\nPublic\n\n\nEkinci 2014\n100\nBevacizumabRanibizumab\n5.16.5\n0.220.24\n484490\nPublic\n\n\nIshibashi 2014\n233\nPegaptanibSham\n4\n0.56\n \nIndustry\n\n\nKorobelnik 2014\n268\nAfliberceptLaser\n8.52.4\n0.50\n \nIndustry\n\n\nLopez‐Galvez 2014\n83\nRanibizumabLaser\n5.32.1\n \n \nIndustry\n\n\nLUCIDATE 2014\n33\nLaserRanibizumab\n2.69\n0.420.30\n489455\nNo details\n\n\nMacugen 2005\n86\nPegaptanibSham\n54.5\n0.560.58\n476423\nIndustry\n\n\nMacugen 2011\n260\nPegaptanibSham\n8.38.4\n0.560.58\n442465\nIndustry\n\n\nRELATION 2012\n128\nLaserRanibizumab‐PL\n \n \n \nIndustry\n\n\nNepomuceno 2013\n60\nBevacizumabRanibizumab\n9.87.7\n0.600.63\n451421\nPublic\n\n\nREAD2 2009\n115\nLaserRanibizumabRanibizumab‐PL\n4.45.32.9\n0.600.540.60\n228190263\nIndustry\n\n\nRESOLVE 2010\n151\nRanibizumabSham\n10.28.9\n0.500.48\n455449\nIndustry\n\n\nRESPOND 2013\n203\nLaserRanibizumabRanibizumab‐PL\n9.28.8\n0.460.440.40\n458448422\nIndustry\n\n\nRESTORE 2011\n343\nLaserRanibizumabRanibizumab‐PL\n7.376.8\n0.460.400.42\n412427416\nIndustry\n\n\nREVEAL 2015\n390\nLaserRanibizumabRanibizumab‐PL\n1.97.87\n0.540.520.52\n395419430\nIndustry\n\n\nSoheilian 2007\n85\nBevacizumabLaser\n \n0.710.55\n352319\nPublic\n\n\nTurkoglu 2015\n70\nLaserRanibizumab\n \n0.840.80\n460488\nNone reported\n\n\nWiley 2016\n124\nBevacizumabRanibizumab\n33\n0.42\n477\nPublic\n\n\n\nOpen in a new tab\n\nDL: plus deferred laser \nPL: plus prompt laser\n(*): median, not mean, available and reported\nSelective reporting\nComparison adjusted funnel plots showed some asymmetry for the outcome 'gain of 3 or more VA lines', but no specific direct comparison seemed to be affected (Figure 12).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Figure 3 presents the corresponding networks' structure.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4, Figure 5 and Figure 6 present forest plots with effects for each study, estimates from direct pairwise meta‐analysis and mixed estimate from the network meta‐analysis.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Mean risk of bias was low for mixed and direct comparisons among aflibercept, bevacizumab and ranibizumab for all efficacy outcomes, except for the comparison between bevacizumab and ranibizumab regarding mean BCVA change and mean CRT change, which were judged at unclear risk of bias (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "DRCRnet 2015 found that such subgroup differences were attenuated at two years.Safety at the longest available follow‐up\nTable 9 presents the number of studies (participants/eyes) in the network for safety outcomes at the longest available follow‐up, and Figure 8 presents the corresponding network structure.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Figure 9, Figure 10 and Figure 11 present forest plots for each study as well as their direct meta‐analysis and mixed estimates from the network meta‐analysis.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Regarding ATC arterial thromboembolic events and all‐cause death, risk of bias was low for aflibercept versus ranibizumab but it was unclear or high for bevacizumab versus ranibizumab (Figure 7).Quality of the evidence\nSee above for the discussion of risk of bias of mixed evidence in pairwise comparisons of interest.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Study\nParticipants\nInterventions\n\nMean n.injections\n\n\nVisualacuity (logMAR)\n\n\nRetinalthickness (µm)\n\n\nStudysponsor\n\n\n\nAhmadieh 2008\n78\nBevacizumabSham\n \n \n \nNone reported\n\n\nBOLT 2010\n80\nBevacizumabLaser\n9*3*\n0.590.61\n507482\nPublic\n\n\nDA VINCI 2011\n89\nAfliberceptLaser\n3.6 to 5.51.7\n0.55\n441\nIndustry\n\n\nDRCRnet 2010\n668\nLaserRanibizumab‐DLRanibizumab‐PL\n3*9*8*\n0.380.390.38\n \nPublic\n\n\nDRCRnet 2015\n620\nAfliberceptBevacizumabRanibizumab\n9.29.49.7\n0.40\n412414407\nPublic\n\n\nEkinci 2014\n100\nBevacizumabRanibizumab\n5.16.5\n0.220.24\n484490\nPublic\n\n\nIshibashi 2014\n233\nPegaptanibSham\n4\n0.56\n \nIndustry\n\n\nKorobelnik 2014\n268\nAfliberceptLaser\n8.52.4\n0.50\n \nIndustry\n\n\nLopez‐Galvez 2014\n83\nRanibizumabLaser\n5.32.1\n \n \nIndustry\n\n\nLUCIDATE 2014\n33\nLaserRanibizumab\n2.69\n0.420.30\n489455\nNo details\n\n\nMacugen 2005\n86\nPegaptanibSham\n54.5\n0.560.58\n476423\nIndustry\n\n\nMacugen 2011\n260\nPegaptanibSham\n8.38.4\n0.560.58\n442465\nIndustry\n\n\nRELATION 2012\n128\nLaserRanibizumab‐PL\n \n \n \nIndustry\n\n\nNepomuceno 2013\n60\nBevacizumabRanibizumab\n9.87.7\n0.600.63\n451421\nPublic\n\n\nREAD2 2009\n115\nLaserRanibizumabRanibizumab‐PL\n4.45.32.9\n0.600.540.60\n228190263\nIndustry\n\n\nRESOLVE 2010\n151\nRanibizumabSham\n10.28.9\n0.500.48\n455449\nIndustry\n\n\nRESPOND 2013\n203\nLaserRanibizumabRanibizumab‐PL\n9.28.8\n0.460.440.40\n458448422\nIndustry\n\n\nRESTORE 2011\n343\nLaserRanibizumabRanibizumab‐PL\n7.376.8\n0.460.400.42\n412427416\nIndustry\n\n\nREVEAL 2015\n390\nLaserRanibizumabRanibizumab‐PL\n1.97.87\n0.540.520.52\n395419430\nIndustry\n\n\nSoheilian 2007\n85\nBevacizumabLaser\n \n0.710.55\n352319\nPublic\n\n\nTurkoglu 2015\n70\nLaserRanibizumab\n \n0.840.80\n460488\nNone reported\n\n\nWiley 2016\n124\nBevacizumabRanibizumab\n33\n0.42\n477\nPublic\n\n\n\nOpen in a new tab\n\nDL: plus deferred laser \nPL: plus prompt laser\n(*): median, not mean, available and reported\nSelective reporting\nComparison adjusted funnel plots showed some asymmetry for the outcome 'gain of 3 or more VA lines', but no specific direct comparison seemed to be affected (Figure 12).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Figure 3 presents the corresponding networks' structure.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4, Figure 5 and Figure 6 present forest plots with effects for each study, estimates from direct pairwise meta‐analysis and mixed estimate from the network meta‐analysis.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Mean risk of bias was low for mixed and direct comparisons among aflibercept, bevacizumab and ranibizumab for all efficacy outcomes, except for the comparison between bevacizumab and ranibizumab regarding mean BCVA change and mean CRT change, which were judged at unclear risk of bias (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 3 presents the corresponding networks' structure.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 4, Figure 5 and Figure 6 present forest plots with effects for each study, estimates from direct pairwise meta‐analysis and mixed estimate from the network meta‐analysis.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Mean risk of bias was low for mixed and direct comparisons among aflibercept, bevacizumab and ranibizumab for all efficacy outcomes, except for the comparison between bevacizumab and ranibizumab regarding mean BCVA change and mean CRT change, which were judged at unclear risk of bias (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Safety at the longest available follow‐up\nTable 9 presents the number of studies (participants/eyes) in the network for safety outcomes at the longest available follow‐up, and Figure 8 presents the corresponding network structure.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Figure 9, Figure 10 and Figure 11 present forest plots for each study as well as their direct meta‐analysis and mixed estimates from the network meta‐analysis.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Regarding ATC arterial thromboembolic events and all‐cause death, risk of bias was low for aflibercept versus ranibizumab but it was unclear or high for bevacizumab versus ranibizumab (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Table 9 presents the number of studies (participants/eyes) in the network for safety outcomes at the longest available follow‐up, and Figure 8 presents the corresponding network structure.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Figure 9, Figure 10 and Figure 11 present forest plots for each study as well as their direct meta‐analysis and mixed estimates from the network meta‐analysis.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Regarding ATC arterial thromboembolic events and all‐cause death, risk of bias was low for aflibercept versus ranibizumab but it was unclear or high for bevacizumab versus ranibizumab (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Study\nParticipants\nInterventions\n\nMean n.injections\n\n\nVisualacuity (logMAR)\n\n\nRetinalthickness (µm)\n\n\nStudysponsor\n\n\n\nAhmadieh 2008\n78\nBevacizumabSham\n \n \n \nNone reported\n\n\nBOLT 2010\n80\nBevacizumabLaser\n9*3*\n0.590.61\n507482\nPublic\n\n\nDA VINCI 2011\n89\nAfliberceptLaser\n3.6 to 5.51.7\n0.55\n441\nIndustry\n\n\nDRCRnet 2010\n668\nLaserRanibizumab‐DLRanibizumab‐PL\n3*9*8*\n0.380.390.38\n \nPublic\n\n\nDRCRnet 2015\n620\nAfliberceptBevacizumabRanibizumab\n9.29.49.7\n0.40\n412414407\nPublic\n\n\nEkinci 2014\n100\nBevacizumabRanibizumab\n5.16.5\n0.220.24\n484490\nPublic\n\n\nIshibashi 2014\n233\nPegaptanibSham\n4\n0.56\n \nIndustry\n\n\nKorobelnik 2014\n268\nAfliberceptLaser\n8.52.4\n0.50\n \nIndustry\n\n\nLopez‐Galvez 2014\n83\nRanibizumabLaser\n5.32.1\n \n \nIndustry\n\n\nLUCIDATE 2014\n33\nLaserRanibizumab\n2.69\n0.420.30\n489455\nNo details\n\n\nMacugen 2005\n86\nPegaptanibSham\n54.5\n0.560.58\n476423\nIndustry\n\n\nMacugen 2011\n260\nPegaptanibSham\n8.38.4\n0.560.58\n442465\nIndustry\n\n\nRELATION 2012\n128\nLaserRanibizumab‐PL\n \n \n \nIndustry\n\n\nNepomuceno 2013\n60\nBevacizumabRanibizumab\n9.87.7\n0.600.63\n451421\nPublic\n\n\nREAD2 2009\n115\nLaserRanibizumabRanibizumab‐PL\n4.45.32.9\n0.600.540.60\n228190263\nIndustry\n\n\nRESOLVE 2010\n151\nRanibizumabSham\n10.28.9\n0.500.48\n455449\nIndustry\n\n\nRESPOND 2013\n203\nLaserRanibizumabRanibizumab‐PL\n9.28.8\n0.460.440.40\n458448422\nIndustry\n\n\nRESTORE 2011\n343\nLaserRanibizumabRanibizumab‐PL\n7.376.8\n0.460.400.42\n412427416\nIndustry\n\n\nREVEAL 2015\n390\nLaserRanibizumabRanibizumab‐PL\n1.97.87\n0.540.520.52\n395419430\nIndustry\n\n\nSoheilian 2007\n85\nBevacizumabLaser\n \n0.710.55\n352319\nPublic\n\n\nTurkoglu 2015\n70\nLaserRanibizumab\n \n0.840.80\n460488\nNone reported\n\n\nWiley 2016\n124\nBevacizumabRanibizumab\n33\n0.42\n477\nPublic\n\n\n\nOpen in a new tab\n\nDL: plus deferred laser \nPL: plus prompt laser\n(*): median, not mean, available and reported\nSelective reporting\nComparison adjusted funnel plots showed some asymmetry for the outcome 'gain of 3 or more VA lines', but no specific direct comparison seemed to be affected (Figure 12).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Selective reporting\nComparison adjusted funnel plots showed some asymmetry for the outcome 'gain of 3 or more VA lines', but no specific direct comparison seemed to be affected (Figure 12).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Comparison adjusted funnel plots showed some asymmetry for the outcome 'gain of 3 or more VA lines', but no specific direct comparison seemed to be affected (Figure 12).",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "The proportion of patients who discontinued the study was 7.5% in the ranibizumab arm, 13.6% in the ranibizumab þ active laser treatment arm, and 17.6% in the laser treatment arm (Fig 2, available at www.aaojournal.org).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Adverse events (range, 3.0%‐6.8%) were the most common reason for discontinuation across all treatment arms (Fig 2, available at www.aaojournal.org).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The proportion of patients who discontinued the study was 7.5% in the ranibizumab arm, 13.6% in the ranibizumab þ active laser treatment arm, and 17.6% in the laser treatment arm (Fig 2, available at www.aaojournal.org).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Adverse events (range, 3.0%‐6.8%) were the most common reason for discontinuation across all treatment arms (Fig 2, available at www.aaojournal.org).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Dynamic randomization was used to obtain approximately a 1:1:1 ratio among groups (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Dynamic randomization was used to obtain approximately a 1:1:1 ratio among groups (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Dynamic randomization was used to obtain approximately a 1:1:1 ratio among groups (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Dynamic randomization was used to obtain approximately a 1:1:1 ratio among groups (Fig 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  }
]